Biogen, Eisai Alzheimer’s Drug Lecanemab Gets ‘Fast Track’ Designation From FDA

A sign marks a Biogen facility in Cambridge, Mass., on March 9, 2020. Brian Snyder/Reuters

Biogen Inc. and Japanese partner Eisai Co. said on Thursday the U.S. Food and Drug Administration (FDA) had granted “fast track” designation to their experimental therapy lecanemab for the treatment of early Alzheimer’s disease.

The FDA had granted “breakthrough” therapy designation to the drug earlier this year.